| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20043261 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20017750 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20038791 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20053858 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20053624 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015273 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015272 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015536 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20014966 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015563 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BCL2 |
|---|---|
| DrugBank ID | DB01248 |
| Drug Name | Docetaxel |
| Target ID | BE0000246 |
| UniProt ID | P10415 |
| Regulation Type | |
| PubMed IDs | 15161985; 15277270; 15643508; 15685445; 15714982; 17674353 |
| Citations | Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8.@@Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83.@@Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64.@@Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1.@@Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302.@@Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54. |
| Groups | Approved; Investigational |
| Direct Classification | Taxanes and derivatives |
| SMILES | [H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1 |
| Pathways | Docetaxel Action Pathway |
| PharmGKB | PA449383 |
| ChEMBL | CHEMBL92 |
